1. Início
  2. Faculdade de Medicina - FM
  3. Departamento de Psiquiatria - FM/MPS
  4. Artigos e Materiais de Revistas Científicas - FM/MPS
Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/23446
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorBRIETZKE, E.-
dc.contributor.authorSCHEINBERG, M.-
dc.contributor.authorLAFER, B.-
dc.date.accessioned2017-11-27T16:34:39Z-
dc.date.available2017-11-27T16:34:39Z-
dc.date.issued2011-
dc.identifier.citationMEDICAL HYPOTHESES, v.76, n.1, p.21-23, 2011-
dc.identifier.issn0306-9877-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/23446-
dc.description.abstractBipolar disorder (BD) is a chronic, severe, and highly disabling psychiatric disorder. Its underlying neurobiology remains largely unclear. A significant body of evidence indicates that inflammatory activation expressed by increased cytokines is relevant in its pathophysiology. IL-6 is one of the most important cytokines involved in the pathogenesis of immune and inflammatory disorders. Several studies recently showed increased levels of IL-6 in manic and depressive episodes and also during euthymia in subjects with BD. Tocilizumab is an IL-6 receptor antagonist being marketed for the treatment of rheumatoid arthritis and Castleman's disease. In this article we discuss the possibility that tocilizumab may have a therapeutic role in treatment of BD through its anti-inflammatory action.-
dc.description.sponsorshipCAPES (Brazil)-
dc.description.sponsorshipFUMCAD (Brazil)-
dc.description.sponsorshipCNPq-
dc.description.sponsorshipFAPESP (Brazil)-
dc.language.isoeng-
dc.publisherCHURCHILL LIVINGSTONE-
dc.relation.ispartofMedical Hypotheses-
dc.rightsrestrictedAccess-
dc.subject.otherrheumatoid-arthritis-
dc.subject.othercellular plasticity-
dc.subject.othermood stabilizers-
dc.subject.othermessenger-rna-
dc.subject.otherbrain-
dc.subject.otherpathophysiology-
dc.subject.otherimbalance-
dc.subject.othercytokines-
dc.subject.otherimpairment-
dc.subject.otherexpression-
dc.titleTherapeutic potential of interleukin-6 antagonism in bipolar disorder-
dc.typearticle-
dc.rights.holderCopyright CHURCHILL LIVINGSTONE-
dc.identifier.doi10.1016/j.mehy.2010.08.021-
dc.identifier.pmid20832177-
dc.subject.wosMedicine, Research & Experimental-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-
hcfmusp.description.beginpage21-
hcfmusp.description.endpage23-
hcfmusp.description.issue1-
hcfmusp.description.volume76-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000286918400007-
hcfmusp.origem.id2-s2.0-78650179092-
hcfmusp.publisher.cityEDINBURGH-
hcfmusp.publisher.countrySCOTLAND-
hcfmusp.relation.referenceAn MM, 2010, EUR J CLIN PHARMACOL, V66, P49, DOI 10.1007/s00228-009-0754-0-
hcfmusp.relation.referenceFountoulakis KN, 2008, INT J NEUROPSYCHOPH, V11, P999, DOI 10.1017/S1461145708009231-
hcfmusp.relation.referencePadmos RC, 2008, ARCH GEN PSYCHIAT, V65, P395, DOI 10.1001/archpsyc.65.4.395-
hcfmusp.relation.referenceMcIntyre RS, 2007, CURR OPIN PSYCHIATR, V20, P406, DOI 10.1097/YCO.0b013e3281938102-
hcfmusp.relation.referenceNishimoto N, 2009, ANN RHEUM DIS, V68, P1580, DOI 10.1136/ard.2008.092866-
hcfmusp.relation.referenceVan Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3-
hcfmusp.relation.referenceKim YK, 2007, J AFFECT DISORDERS, V104, P91, DOI 10.1016/j.jad.2007.02.018-
hcfmusp.relation.referenceO'Brien SM, 2006, J AFFECT DISORDERS, V90, P263, DOI 10.1016/j.jad.2005.11.015-
hcfmusp.relation.referenceBowden CL, 2008, BRAIN RES, V1235, P92, DOI 10.1016/j.brainres.2008.05.084-
hcfmusp.relation.referenceStrand V, 2010, DRUGS, V70, P121, DOI 10.2165/11531980-000000000-00000-
hcfmusp.relation.referencePaul-Pletzer K, 2006, DRUGS TODAY, V42, P559, DOI 10.1358/dot.2006.42.9.1025692-
hcfmusp.relation.referenceKronfol Z, 2000, AM J PSYCHIAT, V157, P683, DOI 10.1176/appi.ajp.157.5.683-
hcfmusp.relation.referenceIwakura Y, 2008, IMMUNOL REV, V226, P57, DOI 10.1111/j.1600-065X.2008.00699.x-
hcfmusp.relation.referenceKim YK, 2007, PROG NEURO-PSYCHOPH, V31, P1044, DOI 10.1016/j.pnpbp.2007.03.004-
hcfmusp.relation.referenceKnijff EM, 2007, BIPOLAR DISORD, V9, P743, DOI 10.1111/j.1399-5618.2007.00444.x-
hcfmusp.relation.referencePedersen BK, 2005, BRAIN BEHAV IMMUN, V19, P371, DOI 10.1016/j.bbi.2005.04.008-
hcfmusp.relation.referenceSchloesser RJ, 2008, NEUROPSYCHOPHARMACOL, V33, P110, DOI 10.1038/sj.npp.1301575-
hcfmusp.relation.referenceMihara M, 2005, EXPERT OPIN BIOL TH, V5, P683, DOI 10.1517/14712598.5.5.683-
hcfmusp.relation.referenceSCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x-
hcfmusp.relation.referenceBrietzke E, 2008, PROG NEURO-PSYCHOPH, V32, P1355, DOI 10.1016/j.pnpbp.2008.01.006-
hcfmusp.relation.referenceKessler RC, 2007, WORLD PSYCHIATRY, V6, P168-
hcfmusp.relation.referenceBettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753-
hcfmusp.relation.referenceKupfer DJ, 2005, JAMA-J AM MED ASSOC, V293, P2528, DOI 10.1001/jama.293.20.2528-
hcfmusp.relation.referenceIrwin MR, 2007, BRAIN BEHAV IMMUN, V21, P374, DOI 10.1016/j.bbi.2007.01.010-
hcfmusp.relation.referenceNishimoto N, 2006, CURR OPIN RHEUMATOL, V18, P277, DOI 10.1097/01.bor.0000218949.19860.d1-
hcfmusp.relation.referenceWingo AP, 2009, BIPOLAR DISORD, V11, P113, DOI 10.1111/j.1399-5618.2009.00665.x-
hcfmusp.relation.referenceKishimoto T, 2005, ANNU REV IMMUNOL, V23, P1, DOI 10.1146/annurev.immunol.23.021704.115806-
hcfmusp.relation.referenceKoike R, 2009, MOD RHEUMATOL, V19, P351, DOI 10.1007/s10165-009-0197-6-
hcfmusp.relation.referenceZarate CA, 2000, PSYCHIAT QUART, V71, P309-
hcfmusp.relation.referenceBachmann RF, 2005, MOL NEUROBIOL, V32, P173, DOI 10.1385/MN:32:2:173-
hcfmusp.relation.referenceBelmaker RH, 2004, NEW ENGL J MED, V351, P476, DOI 10.1056/NEJMra035354-
hcfmusp.relation.referenceBrietzke E, 2009, J AFFECT DISORDERS, V116, P1079-
hcfmusp.relation.referenceFletcher MA, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-96-
hcfmusp.relation.referenceMAES M, 1995, J PSYCHIAT RES, V29, P141, DOI 10.1016/0022-3956(94)00049-W-
hcfmusp.relation.referenceOrtiz-Dominguez A, 2007, BIPOLAR DISORD, V9, P596, DOI 10.1111/j.1399-5618.2007.00493.x-
hcfmusp.relation.referencePan WH, 1999, ADV DRUG DELIVER REV, V36, P291, DOI 10.1016/S0169-409X(98)00086-6-
hcfmusp.relation.referenceSiddiqui MA, 2007, CURR OPIN RHEUMATOL, V19, P08-
hcfmusp.relation.referenceSiddiqui MAA, 2007, CURR OPIN RHEUMATOL, V19, P308, DOI 10.1097/01.bor.0000265447.48722.04-
hcfmusp.relation.referenceSuzuki M, 2009, RHEUMATOL INT, V30, P310-
dc.description.indexMEDLINE-
dc.identifier.eissn1532-2777-
hcfmusp.citation.scopus30-
hcfmusp.scopus.lastupdate2024-04-12-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MPS
Departamento de Psiquiatria - FM/MPS

Artigos e Materiais de Revistas Científicas - LIM/21
LIM/21 - Laboratório de Neuroimagem em Psiquiatria


Files in This Item:
File Description SizeFormat 
art_BRIETZKE_Therapeutic_potential_of_interleukin6_antagonism_in_bipolar_disorder_2011.PDF
  Restricted Access		publishedVersion (English)218.32 kBAdobe PDFView/Open Request a copy
Show simple item record

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.